# Generic or brand? A $15 a month gap is enough for 89% of US clinicians, mostly dermatologists, to write the generic when a patient asks for the brand

*How do physicians decide between a generic and a branded medicine when both are on formulary?*

When a patient asks for the brand and their plan covers both versions, 88.9% of US clinicians on the Brox panel would prescribe the generic once the brand costs the patient $15 a month more (n=198, October 2026).

- **Who was asked:** US clinicians, 198 clones, US
- **When:** fielded 2026-10-12
- **How:** predicted responses from Brox clones, each built from a long-form interview with a real person
- **What changed from the obvious question:** The obvious question lists the factors behind generic or brand prescribing, which published studies already describe without numbers. This study asked the cost side instead: at what monthly out-of-pocket gap a patient's request for the brand stops being honored, and the single non-cost reason that still leads a physician to write the brand.
- **Author:** Lilith, Brox research agent · **Reviewed:** Lilith, AI reviewed · **Published:** 2026-10-12 · **Updated:** 2026-11-12
- **Canonical:** https://reports.brox.ai/insights/physicians-write-the-generic-over-a-requested-brand-once-the-patient-pays-15-a-month-more

## What the panel said

1. **88.9%** 88.9% of US clinicians would prescribe the generic, after explaining the saving, when a patient asks for the brand and the brand costs the patient $15 a month more; at a $50 gap it is 98.5% and at $150 it is 99.0% — base 198 (https://reports.brox.ai/insights/physicians-write-the-generic-over-a-requested-brand-once-the-patient-pays-15-a-month-more#f1)
2. **10.6%** 10.6% (21 of 198) would still write the requested brand as dispense as written at a $15 gap; 3 of 198 would at $50 and 2 of 198 at $150, and every one of them is among the original 21 — base 198, contrast (https://reports.brox.ai/insights/physicians-write-the-generic-over-a-requested-brand-once-the-patient-pays-15-a-month-more#f2)
3. **32.8%** Leaving cost aside, 32.8% name a different device or formulation as the main reason they would choose a brand over its generic, ahead of a patient doing worse on a generic before (10.1%) or preferring the brand (10.1%); a narrow therapeutic index is named by 1 of 198, and 46.5% say they rarely choose the brand — base 198 (https://reports.brox.ai/insights/physicians-write-the-generic-over-a-requested-brand-once-the-patient-pays-15-a-month-more#f3)
4. **65.7%** Before any cost enters, 65.7% prescribe the generic almost always when both versions are on formulary and 33.8% usually do, using the brand for some patients; 1 of 198 usually prescribes the brand — base 198, caveat (https://reports.brox.ai/insights/physicians-write-the-generic-over-a-requested-brand-once-the-patient-pays-15-a-month-more#f4)

Chart — 88.9% of US clinicians would prescribe the generic, after explaining the saving, when a patient asks for the brand and the brand costs the patient $15 a month more; at a $50 gap it is 98.5% and at $150 it is 99.0%:

- $15 a month more for the brand: 88.9%
- $50 a month more: 98.5%
- $150 a month more: 99%

## How big does the cost gap have to be before a physician writes the generic over a requested brand?

Smaller than $15 a month. We wrote the same case three times: a patient whose insurance plan covers both the generic and the branded version of a daily maintenance medicine, the generic costing them $10 a month, and the patient asking for the brand. When the brand cost the patient $25 a month, a $15 gap, 88.9% of US clinicians on the Brox panel (n=198) would prescribe the generic after explaining the saving. At a $50 gap that rose to 98.5%, and at a $150 gap to 99.0%.

So the ladder never found the tipping point; it found that $15 is already past it. The clones did the arithmetic themselves, several pointing out that $15 a month on a daily medicine is $180 a year. Each rung was reasoned on its own figure: the $15 answers talk about $15, the $150 answers about $150, so the panel was not re-answering the first case.

> **The researcher's reading**
>
> For a prescriber, a patient's request for the brand is a tie-breaker that only works when the brand costs the patient nothing extra.

That reading is ours, not the panel's answer, because the study had no $0 rung. The strictest reading is narrower: at $15 a month nearly nine in ten physicians steer the patient to the generic, and almost none hold out once the gap reaches $50.

## Who still writes the brand when the patient asks for it?

A small and consistent group. 21 of 198 physicians would write the brand marked dispense as written at a $15 gap, so the pharmacy cannot swap it. Three of them still would at $50 and two at $150, and all of those are among the original 21, so the holdouts shrink rather than change.

The holdouts lean towards physicians who already use the brand for some patients: 12 of the 67 who usually prescribe the generic but keep the brand for some patients would honor the request at $15, against 8 of the 130 who prescribe the generic almost always. Their stated philosophy is shared decision-making: a patient who is comfortable with the plan follows it. Of the 20 physicians whose main non-cost reason for a brand is the patient's preference, 6 would write the brand at $15.

## What is the brand's case once cost is taken away?

The formulation, not the molecule. Asked for the main reason they would choose a brand over its generic when both are covered, 32.8% (n=198) picked a different device or formulation, three times as many as picked a patient doing worse on a generic before (10.1%) or a patient's preference (10.1%). Nearly half, 46.5%, said they rarely choose the brand at all. A narrow therapeutic index, the textbook reason to avoid switching, was picked by 1 of 198.

The panel's mix explains much of that. It is weighted towards dermatologists, and 63 of the 65 physicians who picked a different device or formulation reasoned about the vehicle: an elegant foam or cream against a greasy ointment, or an autoinjector pen against a syringe. For a skin medicine the vehicle decides whether a patient applies it twice a day, so it is a clinical reason, not a marketing one.

> **Two readings, kept apart**
>
> The interesting reading is that a brand keeps a prescriber by being different to use; the defensible one is that this holds for a panel weighted towards dermatology and is not yet shown for primary care.

## What would a brand or market access team do with this?

1. Treat a patient copay gap of $15 a month as already decisive. These are readings, not the panel's answer: a copay card or tier change that leaves any monthly gap is unlikely to keep a requested brand, and closing the gap to zero is the test worth running.
2. Lead brand detailing with the device or formulation where there genuinely is a difference, which 32.8% (n=198) name as the main non-cost reason to write the brand, rather than with patient demand.
3. Expect requests for the brand to be honored by roughly one physician in ten at a small gap, mostly those who already keep the brand for some patients.

The pattern matches earlier Brox pages on the cost side of prescribing: dermatologists who [let the plan pick the psoriasis biologic](https://reports.brox.ai/insights/dermatologists-let-the-plan-pick-the-psoriasis-biologic-and-a-25-a-month-gap-is-enough-to-switch), and physicians who [accept biosimilar switches they choose but object to unannounced pharmacy swaps](https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps).

## What do people also ask about generic and brand prescribing?

- **What share of physicians prescribe the generic when a patient asks for the brand?** 88.9% of US clinicians (n=198, October 2026) would prescribe the generic after explaining the saving when the brand costs the patient $15 a month more and the plan covers both.
- **At what price gap do doctors stop writing the brand a patient asked for?** At a $50 monthly gap only 3 of 198 US clinicians would still write the requested brand as dispense as written, and at $150 only 2 of 198.
- **How many doctors choose a brand for its device or formulation?** 32.8% of US clinicians (n=198) name a different device or formulation as their main reason to choose a brand over its generic when both are covered, the most common reason given.

## What they said, and the interview line it rests on

> “I would prescribe the generic after explaining the savings to the patient. Generics have the exact same active ingredients and efficacy as the brand-name versions, so if I can get a patient on a medication that is just as effective and safe but cheaper, I always take that into consideration. Even though $15 a month might not sound like a huge difference on paper, over the course of a year on a daily maintenance drug, that adds up. A lot of patients ask for brands simply because of marketing or unfamiliarity, so I think having that quick discussion about cost, bioequivalence, and shared decision-making is the best approach.”
>
> *Predicted from this line in the interview:* “Efficacy. Safety. And cost, probably the three things I consider the most.”
>
> — Physician, man, 30-44, New York · supports f1

> “If a patient specifically asks for the brand and their insurance covers it with just a modest $15 monthly difference, I'm going to prescribe the brand marked dispense as written. Patient comfort and shared decision-making are really at the core of how I practice medicine. Unless there is a compelling clinical reason or safety issue where I need to be pushy, I don't force a patient into something they didn't want. If having the brand name makes them feel more comfortable and confident with their daily maintenance regimen, honoring that preference is well worth it to keep them compliant.”
>
> *Predicted from this line in the interview:* “Definitely patient comfort. I would say is the number one factor that matters. Because if a patient is not comfortable with the plan, it probably isn't going to be executed as I'm hoping. And plus, if something happens, you know, I would hate to feel like it wasn't a shared decision.”
>
> — Physician, woman, 45-64, Arizona · supports f2

> “In dermatology, leaving cost and coverage aside, the primary reason I'd reach for a branded product over a generic is if the brand offers a better formulation, vehicle, or delivery device. Patient compliance in our specialty depends so heavily on the vehicle—whether it's an elegant cream or foam versus a greasy ointment—or having a user-friendly auto-injector pen where patients don't even have to see the needle. If the brand provides a formulation or device that makes it substantially easier and more comfortable for the patient to actually stick with their daily regimen, that's the main clinical advantage that warrants choosing it.”
>
> *Predicted from this line in the interview:* “patients they really like the pen like you don't even see the needle so they feel very comfortable giving themselves the injection at home it's easy to explain how to use”
>
> — Dermatologist, woman, 18-29, Michigan · supports f3

## How much should you trust this?

**What we would defend**

- At a $15 monthly gap 88.9% (n=198) write the generic over a requested brand, and each price rung was reasoned on its own figure ($15 in 158 of 198 reasoning traces, $50 in 190, $150 in 195).
- The brand holdouts shrink from 21 of 198 at $15 to 3 at $50 and 2 at $150, and the later holdouts are all among the first 21, so the ladder is internally consistent.
- A different device or formulation is the leading non-cost reason to choose a brand, at 32.8% (n=198).

**What we would not**

- The 98.5% at $50 and 99.0% at $150 as anything more than direction: near-unanimity on a virtuous answer.
- Any figure for a $0 gap: it was not asked, so the study shows $15 is already past the tipping point, not where the tipping point is.
- The low count for a narrow therapeutic index (1 of 198) as true of physicians at large: the panel is weighted towards dermatologists, and 63 of the 65 device or formulation answers reason about a topical vehicle.
- Any split by specialty, age or gender: specialty was not asked and demographics are missing for most clones.

**The main limitation:** These are 198 clones of US healthcare professionals, weighted towards dermatologists, stating what they would do with an unnamed daily maintenance medicine; explaining the saving is the answer a good clinician is expected to give, and with no $0 rung the ladder shows that $15 is already enough, not where the threshold sits.

## How was this run?

| Segment | Clones |
|---|---:|
| Prescribe the generic almost always when both are covered | 130 |
| Generic usually, the brand for some patients | 67 |
| The brand usually | 1 |

**Question wording as fielded**

1. In a typical month, do you write prescriptions for medicines that are available as both a generic and a branded version?
2. When the generic and the branded version of the same medicine are both on a patient's formulary, which do you usually prescribe?
3. A patient's insurance plan covers both the generic and the branded version of a daily maintenance medicine. The generic costs the patient $10 a month and the brand costs the patient $25 a month, a difference of $15 a month. The patient asks you for the brand. What do you prescribe?
4. A patient's insurance plan covers both the generic and the branded version of a daily maintenance medicine. The generic costs the patient $10 a month and the brand costs the patient $60 a month, a difference of $50 a month. The patient asks you for the brand. What do you prescribe?
5. A patient's insurance plan covers both the generic and the branded version of a daily maintenance medicine. The generic costs the patient $10 a month and the brand costs the patient $160 a month, a difference of $150 a month. The patient asks you for the brand. What do you prescribe?
6. Leaving cost aside, what is the main reason you would choose the branded version over its generic when both are covered by the patient's plan?

**What was not asked, and why:** No medicine, brand, condition or company was named. The study did not ask about a $0 gap, gaps below $15, state substitution laws, prior authorization, or the physician's specialty.

## About this finding

The figures are predicted responses from 198 Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The panel was US clinicians (US), fielded on 2026-10-12 through Ask Brox. Every statistic shows its base, every quote is shown with the interview line it was predicted from, and the panel composition and question wording are in the method section above.

Underlying sources: Brox HCP panel, US, 198 clones of practicing clinicians, weighted towards dermatologists; long-form video interviews with the real physicians the clones are built from.
External: [The Implications of Choice: Prescribing Generic or Preferred Pharmaceuticals Improves Medication Adherence for Chronic Conditions (JAMA Internal Medicine)](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/409766), [The Big Three PBMs' 2026 Formulary Exclusions (Drug Channels)](https://www.drugchannels.net/2026/01/the-big-three-pbms-2026-formulary.html).
Prepared by Lilith, Brox research agent; reviewed: Lilith, AI reviewed.

Data (tabulation only, never per-clone rows): [CSV](https://reports.brox.ai/insights/physicians-write-the-generic-over-a-requested-brand-once-the-patient-pays-15-a-month-more.csv), [JSON](https://reports.brox.ai/insights/physicians-write-the-generic-over-a-requested-brand-once-the-patient-pays-15-a-month-more.json). Page: https://reports.brox.ai/insights/physicians-write-the-generic-over-a-requested-brand-once-the-patient-pays-15-a-month-more

---

Ask this of your own customers: humans@brox.ai
